Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Minnesota: - Riverwood Healthcare Center — Aitkin, Minnesota
- Essentia Health - Baxter Clinic — Baxter, Minnesota
- Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
- Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
- Fairview Ridges Hospital — Burnsville, Minnesota
Phase 2, Phase 3 Recruiting Network
This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that …
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06616584
Sites in Minnesota: - Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
- Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
- Mercy Hospital — Coon Rapids, Minnesota
- Essentia Health - Deer River Clinic — Deer River, Minnesota
- Essentia Health Cancer Center — Duluth, Minnesota
Phase 3 Recruiting NIH
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in Minnesota: - Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
- Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
- Mercy Hospital — Coon Rapids, Minnesota
- Essentia Health - Deer River Clinic — Deer River, Minnesota
- Essentia Health Cancer Center — Duluth, Minnesota
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Minnesota: - Minnesota Oncology Hematology PA-Chaska — Chaska, Minnesota
- Fairview Clinics and Surgery Center Maple Grove — Maple Grove, Minnesota
- Hennepin County Medical Center — Minneapolis, Minnesota
- University of Minnesota/Masonic Cancer Center — Minneapolis, Minnesota
- Monticello Cancer Center — Monticello, Minnesota
Phase 2, Phase 3 Recruiting Industry
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Minnesota: - USOR - Minnesota Oncology - Burnsville — Burnsville, Minnesota
- Local Institution - 007-589A — Edina, Minnesota
- Local Institution - Unk006 — Minneapolis, Minnesota
- Local Institution - 007-822 — Minneapolis, Minnesota
- Local Institution - 007-830 — Rochester, Minnesota
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Minnesota: - Minnesota Oncology Hematology, PA — Burnsville, Minnesota
- Allina Health Cancer Institute - Mercy Hospital — Coon Rapids, Minnesota
- Minnesota Oncology Hematology, PA — Coon Rapids, Minnesota
- Minnesota Oncology Hematology, P.A. — Edina, Minnesota
- Minnesota Oncology Hematology PA — Maple Grove, Minnesota
Phase 3 Recruiting Industry
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in Minnesota: - Clinical Study Sites — Duluth, Minnesota
- Clinical Study Site — Minneapolis, Minnesota
- Clinical Study Site — Saint Paul, Minnesota
Phase 3 Recruiting Industry
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with lo…
Sponsor: AstraZeneca
NCT ID: NCT05211895
Sites in Minnesota: - Research Site — Minneapolis, Minnesota
- Research Site — Rochester, Minnesota
Phase 3 Recruiting Academic/Other
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT02468024
Sites in Minnesota: - Mayo Clinic Rochester — Rochester, Minnesota
Phase 2 Recruiting Network
This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Minnesota: - Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
- Mercy Hospital — Coon Rapids, Minnesota
- Essentia Health - Deer River Clinic — Deer River, Minnesota
- Essentia Health Cancer Center — Duluth, Minnesota
- Fairview Southdale Hospital — Edina, Minnesota
Phase 2 Recruiting Industry
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-smal…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06667076
Sites in Minnesota: - University Of Minnesota — Minneapolis, Minnesota
- Mayo Clinic Rochester — Rochester, Minnesota
Phase 2 Recruiting Industry
This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
Sponsor: Genentech, Inc.
NCT ID: NCT04302025
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Minnesota: - USOR Minnesota Oncology Hematology — Maplewood, Minnesota
Phase 2 Recruiting Academic/Other
This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07293247
Sites in Minnesota: - Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
- Essentia Health - Deer River Clinic — Deer River, Minnesota
- Essentia Health Cancer Center — Duluth, Minnesota
- Essentia Health Saint Mary's Medical Center — Duluth, Minnesota
- Miller-Dwan Hospital — Duluth, Minnesota
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Minnesota: - Research Site 121 — Saint Paul, Minnesota
Phase 2 Recruiting Industry
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combinati…
Sponsor: AstraZeneca
NCT ID: NCT05061550
Sites in Minnesota: - Research Site — Saint Louis Park, Minnesota
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…
Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in Minnesota: - Mayo Rochester — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Industry
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesoth…
Sponsor: A2 Biotherapeutics Inc.
NCT ID: NCT06051695
Sites in Minnesota: - Mayo Clinic Rochester — Rochester, Minnesota
Phase 2 Recruiting Academic/Other
The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab deruxtecan before routine surgery to rem…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07428044
Sites in Minnesota: - Mayo Clinic (Data Collection Only) — Rochester, Minnesota
Phase 2 Recruiting Academic/Other
The primary objective of this single arm, open label, phase II trial is to determine if axelopran use impacts cancer control in patients with advanced cancers of the lung, breast, pancreas, and prostate. The primary study period for assess…
Sponsor: HealthPartners Institute
NCT ID: NCT07354919
Sites in Minnesota: - HealthPartners Frauenshuh Cancer Research Center — Saint Louis Park, Minnesota
- HealthPartners Cancer Center at Regions Hospital — Saint Paul, Minnesota
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Minnesota: - Regions Hospital Cancer Care Center — Saint Paul, Minnesota
Phase 1 Recruiting Industry
This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either di…
Sponsor: Nuvectis Pharma, Inc.
NCT ID: NCT05873686
Sites in Minnesota: - Mayo Clinic Rochester — Rochester, Minnesota
Phase 1 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or met…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06562192
Sites in Minnesota: - Mayo Clinic Rochester — Rochester, Minnesota
Phase 1 Recruiting Industry
This is a phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without paclitaxel and/or trastuzumab or cetuximab, …
Sponsor: Fate Therapeutics
NCT ID: NCT07216105
Sites in Minnesota: - University of Minnesota Masonic Cancer Center — Minneapolis, Minnesota
Phase 1 Recruiting Industry
The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplanta…
Sponsor: Tr1X, Inc.
NCT ID: NCT06462365
Sites in Minnesota: - University of Minnesota — Minneapolis, Minnesota